Tacrolimus is a macrolide immunosuppressant that is widely used in transplant surgery. Both mild and major neurologic side effects have been reported in patients receiving tacrolimus. Reversible posterior leukoencephalopathy syndrome is one of the major tacrolimus induced neurologic side effects. We report a case of a tacrolimus induced isolated lesion of the cerebellum with no supratentorial involvement, presenting as a subacute cerebellar ataxia, which was partially reversible upon discontinuing the tacrolimus.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejpn.2006.01.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Deeply Saddening Life Events Play a Carcinogenic Role by Inducing Mutations in and Genes.
Genes (Basel)
November 2024
Department of Medical Oncology, Pamukkale University School of Medicine, Denizli 20070, Turkey.
Background/objectives: In the past few decades, many studies have been conducted to find out that psychological stress and cancer are closely linked. Moreover, it was reported that stress can induce mutations in gene level. Therefore, in this study we want to examine a relationship between stressful life events, gene mutation and cancer.
View Article and Find Full Text PDFTau phosphorylation suppresses oxidative stress-induced mitophagy via FKBP8 receptor modulation.
PLoS One
January 2025
Department of Anesthesiology & Perioperative Medicine, University of Rochester, Rochester, New York, United States of America.
Article Synopsis
- Neurodegenerative diseases like Alzheimer's are linked to problems with mitochondria, specifically mitophagy, which is the process of removing damaged mitochondria.
- Research indicates that mutated tau proteins can inhibit this process, affecting cell health during oxidative stress.
- In this study, it was found that certain tau mutations reduce levels of a key mitophagy receptor, FKBP8, which could help explain tau's role in mitochondrial dysfunction related to Alzheimer's and suggest FKBP8 as a target for future treatments.
CXCR2 Activated JAK3/STAT3 Signaling Pathway Exacerbating Hepatotoxicity Associated with Tacrolimus.
Drug Des Devel Ther
January 2025
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy & School of Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu, 221004, People's Republic of China.
Purpose: Tacrolimus could induce hepatotoxicity during clinical use, and the mechanism was still unclear, which posed new challenge for the prevention and treatment of tacrolimus-induced hepatotoxicity. The aim of this study was to investigate the mechanism of tacrolimus-induced hepatotoxicity and provide reference for drug development target.
Methods: In this study, biochemical analysis, pathological staining, immunofluorescent staining, immunohistochemical staining, transcriptomic analysis, Western blotting was used to investigate the mechanism of tacrolimus-induced hepatotoxicity in gene knockout mice and Wistar rats.
Drug-induced coagulopathies: a real-world pharmacovigilance study using the FDA adverse event reporting system.
Front Pharmacol
December 2024
Pharmacy Department, Xiamen Fifth Hospital, Xiamen, Fujian, China.
Background: This study aims to investigate adverse drug reaction signals associated with coagulopathies through data mining using the Adverse Event Reporting System (FAERS) of the US Food and Drug Administration. Prompt identification of high-risk drugs provides a valuable basis for enhancing clinical drug safety.
Methods: The adverse event reports related to coagulopathies from Q1 2004 to Q2 2024 were extracted from the ASCII data packages in FAERS.
Tacrolimus-induced thrombotic microangiopathy (TMA) after heart and lung transplantation successfully treated with eculizumab.
Transpl Immunol
December 2024
Pulmonary, Critical Care and Cardiothoracic Surgery, Northwell Health Systems, 300 Community Dr, Manhasset, NY 11030, United States of America.
Introduction: Tacrolimus-induced thrombotic microangiopathy (TMA) causing acute kidney injury (AKI) without systemic features is a rare entity, particularly after non-renal solid organ transplantation.
Case Report: We describe the case of a patient with AKI after combined heart and lung transplantation. Renal biopsy revealed acute thrombotic microangiopathy which ultimately prompted initiation of eculizumab, a monoclonal antibody targeted against complement C5, with subsequent recovery in renal function.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!